Shiga-Toxin E. coli Hemolytic Uremic Syndrome: Review of Management and Long-term Outcome
| Autor: | Ben C Reynolds, David A. McAllister, V. J. Harkins |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0303 health sciences
medicine.medical_specialty biology 030306 microbiology business.industry Adverse outcomes Shiga toxin urologic and male genital diseases female genital diseases and pregnancy complications Pathophysiology Complement system Blockade 03 medical and health sciences 0302 clinical medicine Clinical research hemic and lymphatic diseases Isotonic medicine biology.protein General Earth and Planetary Sciences 030212 general & internal medicine Intensive care medicine business General Environmental Science |
| Zdroj: | Current Pediatrics Reports. 8:16-25 |
| ISSN: | 2167-4841 |
| DOI: | 10.1007/s40124-020-00208-7 |
| Popis: | Purpose of Review We review the pathophysiology of Shiga-Toxin Enteropathogenic–Hemolytic Uremic Syndrome (STEC-HUS), strategies to ameliorate or prevent evolution of STEC-HUS, management and the improved recognition of long-term adverse outcomes. Recent Findings Following on from the preclinical evidence of a role for the complement system in STEC-HUS, the use of complement blocking agents has been the major focus of most recent clinical research. Novel therapies to prevent or lessen HUS have yet to enter the clinical arena. The long-term outcomes of STEC-HUS, similarly to other causes of AKI, are not as benign as previously thought. Summary Optimizing supportive care in STEC-HUS is the only current recommended treatment. The administration of early isotonic fluids may reduce the severity and duration of STEC-HUS. The role of complement blockade in the management of STEC-HUS remains unclear. The long-term sequelae from STEC-HUS are significant and patients with apparent full renal recovery remain at risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink